JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $78 to $79.
March 06, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama reaffirmed an Overweight rating on Apellis Pharmaceuticals and raised the price target to $79.
The increase in price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal for Apellis Pharmaceuticals. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100